Please feel free to contact us for a quote and further discussion with our scientists.
Datasheets
| Specifications | |
|---|---|
| Product Description | VH298 is a cell-permeable VHL inhibitor that binds to the HIF-binding pocket of VHL, blocking HIF-1alpha recognition. It serves as a warhead for constructing bifunctional molecules that recruit VHL E3 ligase activity. |
| Molecular Formula | C27H33N5O4S |
| Molecular Weight (Da) | 523.7 |
| Chemical Name | (2S,4R)-1-[(2S)-2-[(1-cyanocyclopropanecarbonyl)amino]-3,3-dimethylbutanoyl]-4-hydroxy-N-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide |
| Chemical Structure |  |
| Purity | 0.99 |
| Size | 5 mg |
| Physical State | Powder |
| Storage | The power can be stored at 4 °C for 2 years or at -20 °C for 3 years. |
| Target Information | |
|---|---|
| Target Name | VHL |
| Alternative Names | HRCA1, RCA1, VHL1, pVHL |
| Introduction | VHL is the substrate recognition subunit of the CUL2-RBX1-Elongin B/C E3 ubiquitin ligase complex, containing a beta-domain that binds HIF-alpha and an alpha-domain that interacts with Elongin C. It is a tumor suppressor frequently mutated in von Hippel-Lindau disease. |
| Gene ID | 7428 |
| UniProt ID | P40337 |
| Related Disease | Von Hippel-Lindau disease, renal cell carcinoma, hemangioblastoma, pheochromocytoma |
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
